Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial - Leslie Chong | CEO & Managing Director, Imugene Ltd 00:00:00
Ms Chong has 24 years of oncology experience in Phase I – III of clinical program development, including leadership role involvement in two marketed oncology products. She was previously Senior Clinical Program Lead at Genentech, Inc., in San Francisco. Genentech is widely regarded as one of the world’s most successful biotech companies with a strong oncology franchise including the best-selling breast cancer drug Herceptin.
